Invicta Diagnostic IPO Details

SME

Invicta Diagnostic IPO opens for subscription on 01 Dec 2025 and closes on 03 Dec 2025. The IPO will be listed on NSE with the tentative listing date set for 08 Dec 2025.

Invicta Diagnostic IPO price band has been fixed at ₹80 – ₹85 per share.The face value is ₹10 per share with a lot size of 1600.

Invicta Diagnostic IPO total issue size comprises 33,08,800 shares (aggregating up to ₹28.12 Cr.). This includes a fresh issue of 33,08,800 shares (aggregating up to ₹28.12 Cr.). Pre-issue shareholding stands at 92,63,173, which will increase to 1,25,71,973 post-issue.

Invicta Diagnostic IPO Lot Size : Individual Minimum is 2 lots (3,200 shares) amounting to ₹272,000. Individual Maximum is 2 lots (3,200 shares) amounting to ₹272,000. SHNI Minimum is 3 lots (4,800 shares) amounting to ₹408,000. SHNI Maximum is 7 lots (11,200 shares) amounting to ₹952,000. BHNI Minimum is 8 lots (12,800 shares) amounting to ₹1,088,000.

The Lead Managers for Invicta Diagnostic IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Socradamus Capital Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Nikunj Stock Brokers. You can analyze their track record by checking the Market Maker Performance Summary report.

For detailed information, Refer to the Invicta Diagnostic Limited RHP.

Invicta Diagnostic IPO Details

Listing Price : ₹100 at a Premium of 17.65%

Open Date

01 Dec 2025

Close Date

03 Dec 2025

Listing Date

08 Dec 2025

Issue Price

₹80 - ₹85

Face Value

₹10 per share

Lot Size

1600

GMP

₹0

Issue Type

IPO

Listing On

NSE

Type

Book Built Issue

Share holding pre issue

9263173

Share holding post issue

12571973

Total Issue Size

33,08,800 shares (aggregating up to ₹28.12 Cr.)

Fresh Issue

33,08,800 shares (aggregating up to ₹28.12 Cr.)

Offer for Sale

Invicta Diagnostic IPO Subscription

Invicta Diagnostic IPO Application Wise Breakup

Invicta Diagnostic IPO Dates

01 Dec 2025
Opening dateOpen
03 Dec 2025
Closing dateClose
04 Dec 2025
Allotment Date Allotment
05 Dec 2025
Initiation of RefundsRefund
05 Dec 2025
Credit of SharesCredit
08 Dec 2025
Listing dateListing

Invicta Diagnostic IPO Lot Size

Application	Lots	Shares	Amount
Individual Minimum	2	3200	₹272,000
Individual Maximum	2	3200	₹272,000
SHNI Minimum	3	4800	₹408,000
SHNI Maximum	7	11200	₹952,000
BHNI Minimum	8	12800	₹1,088,000

Invicta Diagnostic IPO Reservation

Promoter Holding

Pre Issue:90.52%

Post Issue:66.7%

Promoter Names:

Dr. Ketan Jayantilal Jain, Dr. Sanket Vinod Jain, Rohit Prakash Srivastava, Badal Kailash Naredi, Jayesh Prakash Jain

Documents

› Invicta Diagnostic IPO DRHP

› Invicta Diagnostic IPO RHP

› Anchor Investors in Invicta Diagnostic IPO

› Invicta Diagnostic IPO BOA

Invicta Diagnostic IPO Valuations

ROE:44.28%

ROCE:42.00%

DEBT/EQUITY:0.26

RONW:36.25%

PAT MARGIN:16.38%

PRICE TO BOOK VALUE:5.26

P/E Pre IPO:15.97

P/E Post IPO:21.68

Invicta Diagnostic Financial Information

Period Ended	30 Sep 2025	31 Mar 2025	31 Mar 2024
Assets	34.90	21.22	15.89
Total Income	17.08	30.18	15.90
Profit After Tax	4.08	4.93	3.81
EBITDA	6.77	9.20	7.09
NET Worth	23.68	13.60	8.67
Reserves and Surplus	14.42	5.18	8.54
Total Borrowing	3.72	3.54	3.81
Amount in ₹ Crore

About Invicta Diagnostic IPO

Incorporated in January 2021, Invicta Diagnostic Limited provides a wide range of radiology and pathology services. Operating under the brand “PC Diagnostics”, the company delivers imaging, laboratory testing, pathology, radiology, and teleradiology services through seven diagnostic centres and a central laboratory across Mumbai, Maharashtra.

Trading as PC Diagnostics, Invicta functions as an integrated diagnostic services provider using a hub-and-spoke model across the Mumbai Metropolitan Region. Its network includes:

A flagship hub in Thane West offering full-spectrum pathology and advanced radiology (CT, MRI)
Three additional hubs (Bhayandar, Byculla, Marol) providing specialized diagnostic services
Four spokes in Lower Parel, Sewri, Mazgaon, and Kalwa focused on basic imaging (X-ray, ultrasound) and sample collection.

The company’s test portfolio covers around 60 routine pathology tests, 487 specialised pathology tests, 96 basic radiology tests, and 130 advanced radiology investigations.

Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels
Specialised Tests: Covers molecular diagnostics, immunoassays, infectious disease markers (e.g., dengue, COVID-19), cancer markers, and genetic panels
Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres.

As of May 31, 2025, the company’s medical team includes 5 laboratory doctors, 20 radiologists, and 127 trained technical professionals. On the same date, the organisation employed 105 permanent staff members.

Strength Of Invicta Diagnostic IPO

Expanding presence in Mumbai Metropolitan Region ("MMR") specifically in radiology sector.
Diagnostics provider that offers one-stop solution at affordable price.
Technical capability and technology with IT infrastructure.
Dedicated management team with significant industry experience.
Implementation of Hub and Spoke Model.

Risk Of Invicta Diagnostic IPO

Its business and prospects may be adversely affected if the company is unable to maintain and grow its brand name and brand image.
Any interruptions at its flagship centre and other diagnostic centres may affect the company ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.
Concentrated emphasis on radiology services also exposes it to substantial risks that could adversely impact its operations, financial performance, and long-term growth prospects.
The company operations are concentrated in Mumbai Metropolitan Region ("MMR"), and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.
Its ability to remain competitive may be adversely affected by technological advancements, innovations in diagnostic testing and its ability to access such technology.
The company operates in a highly competitive business environment, and its inability to compete effectively could have an adverse effect on the company business, results of operations and financial condition.
Failures to establish and comply with appropriate quality standards when performing imaging, testing and diagnostics services could result in litigation and liability for it and could materially and adversely affect its reputation and results of operations.
Its may be unable to successfully implement or manage the company growth strategy.
The Restated Financial Information provided in this Red Herring Prospectus have been provided by the Peer Reviewed Chartered Accountants who are not the Statutory Auditors of the Company.
The industry in which the company operates possess various risks and challenges as provided in the Industry Report titled "Industry Report on Diagnostic Industry in India" dated July 22, 2024, which is exclusively prepared for the purposes of the Offer and issued by D&B and is commissioned and paid for by the Company ("D&B Report").